Logo

AbbVie to Discontinue its P-III MERU Trial of Rovalpituzumab Tesirine (Rova-T) as 1L Maintenance Therapy for Patients with Advanced Small-Cell Lung Cancer

Share this

AbbVie to Discontinue its P-III MERU Trial of Rovalpituzumab Tesirine (Rova-T) as 1L Maintenance Therapy for Patients with Advanced Small-Cell Lung Cancer

Shots:

  • The Independent Data Monitoring Committee (IDMC) recommends for the termination of P-III MERU trial due to lack of survival benefits for patients receiving Rova-T vs PBO control arm based on results at a pre-planned interim analysis
  • The P-III MERU trial is discontinued with the closure of R&D program for Rova-T and the trial involves assessing of Rova-T as maintenance therapy following 1L platinum-based chemotherapy in patients with advanced SCLC evaluating its safety and efficacy
  • Rova-T is an investigational ADC targeting cancer-stem cell-associated delta-like protein 3 (DLL3). Additionally- AbbVie oncology portfolio is evaluated in 300+ trials and in more than 20 different tumor type

Click here to read full press release/ article

Ref: AbbVie| Image: AbbVie


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions